Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Jimenez-Fonseca P, Fernandez del Valle A, Solis M, Garcia Carbonero R, Custodio A,
#2133 Clinicopathological Features of the High Grade Pancreatic Neuroendocrine Neoplasms
Introduction: The high grade pancreatic neuroendocrine neoplasms (PanNENs) include well-differentiated tumors (WD-NETs) with elevated proliferation and poorly differentiated carcinomas (PD-NECs).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Delektorskaya V, Solovieva O, Koslov N, Patyutko Y,
Keywords: neuroendocrine, pancreas, neoplasm, grade, survival,
Introduction: Stromal Immune Contexture (SIC) helps predict prognosis in solid Tumors (T) but has been poorly investigated in gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). We tested whether GEP-NENs profiling for adaptive immunity-related SIC markers, as well as inflammatory (COX2),EMT [Beta-catenin (B-cat)] and oncogenic pathway signaling (pS6) markers,could improve Ki67 and/or MO-based prediction of OS and DFS.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Milione M
Authors: Milione M, Miceli R, Pellegrinelli A, Spaggiari P, Tagliabue G,
Keywords: Neuroendocrine, Ki-67, Morphology, Immune contexture, PDL1, Beta-Catenin,
#1780 PD-L1 Is Expressed in a Subset of Pancreatic Neuroendocrine Tumors (pNET)
Introduction: Programmed death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, interacting with two ligands, PD-L1 and PD-L2. The former is expressed in many human cancers and is used as a selection criterion for indication of checkpoint inhibitor therapies. PD-L1 is also a potential target for checkpoint inhibitors in pNET therapy, however no data on prevalence of PD-L1 expression and potential associations to clinico-pathologic features is available.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Saganas C
Authors: Saganas C, Blank A, Franzelli M, Marinoni I, Perren A,
Keywords: neuroendocrine, tumors,
Introduction: Small pancreatic neuroendocrine tumours (pNETs) present a management dilemma between surveillance and resection.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Mills L, Drymousis P, Vashist Y, Burdelski C, Prachalias A,
Keywords: pNET, surveillance, incidental,